Immunomodulators

Last Updated: February 29, 2024

Summary Recommendations

The hyperactive inflammatory response to SARS-CoV-2 infection plays a central role in the pathogenesis of COVID-19. See Therapeutic Management of Hospitalized Adults With COVID-19 and Therapeutic Management of Hospitalized Children With COVID-19 for the COVID-19 Treatment Guidelines Panel’s (the Panel) recommendations on the use of the following immunomodulators in hospitalized patients with COVID-19 according to their disease severity (listed in alphabetical order):

- Abatacept
- Baricitinib (or tofacitinib)
- Dexamethasone
- Infliximab
- Tocilizumab (or sarilumab)

There is insufficient evidence for the Panel to recommend either for or against the use of the following immunomodulators for the treatment of COVID-19:

- Anakinra
- Inhaled corticosteroids
- Vilobelimab

The Panel recommends against the use of canakinumab for the treatment of COVID-19, except in a clinical trial (BIIa).

Each recommendation in the Guidelines receives a rating for the strength of the recommendation (A, B, or C) and a rating for the evidence that supports it (I, IIa, IIb, or III). See Guidelines Development for more information.